Early research (Phase 1)Study completedNCT03101891What this trial is testingRenal Anhydramnios Fetal TherapyWho this might be right forAnhydramniosPotter SyndromeLung Hypoplasia+4 more Johns Hopkins University 55
Not applicableLooking for participantsNCT06728228What this trial is testingAmnioinfusion for Fetal Renal FailureWho this might be right forMulticystic Dysplastic KidneyPolycystic Kidney DiseaseFetal Renal Anomaly+6 more Fetal Care Center, PLLC 35
Large-scale testing (Phase 3)WithdrawnNCT04786574What this trial is testingSee if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)Who this might be right forAutosomal Recessive Polycystic Kidney Disease (ARPKD) Otsuka Pharmaceutical Development & Commercialization, Inc.
Large-scale testing (Phase 3)Looking for participantsNCT04782258What this trial is testingSee if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)Who this might be right forAutosomal Recessive Polycystic Kidney (ARPKD) Otsuka Pharmaceutical Development & Commercialization, Inc. 20